Brad Moore on Leveraging Blockchain to Improve Outcomes for Medical Cannabis Patients | #HashtagFinance

CSE's Barrington Miller chats with Brad Moore, CEO of Global Cannabis Applications Corp. (CSE:APP) about his company's ambitions as a technology company that strives to improve medical cannabis patients' outcomes through the gathering and analysis of deep data.Here's an overview of what Barrington and Brad cover in this edition of the #HashtagFinance podcast:1.10 - Virtual work is nothing new for Brad and his international team.3:35 - GCAC's Israeli technology connection.6:01 - How Brad has applied his military mindset into the cannabis/tech industries.9:53 - The impact of the early 2018 cannabis "craze" on the company.13:54 - Defining 2020 as the year of the (delayed) balance sheet.15:46 - The application of blockchain on their business model.18:20 - Building data points during COVID.19:35 - The differentiator.23:53 - The power of data to improve patient incomes.28:47 - What a potential exit path looks like for the company. Current approval processes for medical treatments generally start with a formulation of elements. The objective of any clinical study is to ensure efficacy, and safety, within a fixed sampling size. However as cannabis is a plant, and each plant is unique, the challenges have been in ensuring that each gram tested would provide a consistent result. In response to these challenges, GCAC has developed a patent-pending data model called, Seed to Seed.GCAC's approach is to measure an individual’s unique treatment experience on a per dosage basis. By digitally measuring both the biometric & anecdotal feedback and comparing that to others using the same or similar products on a large scale, GCAC can provide an averaged efficacy rating for the treatment used. This is accomplished through a proprietary system of mobile applications, heart monitoring biometrics, Artificial Intelligence and machine learning. When integrated with blockchain seed to sale solutions, GCAC technology will be able to recommend “how to treat ailment X with product Y at a given point in time under a set of circumstances”. By securing this information on an EU GDPR complaint blockchain, their data outputs are comparable to results generated by a regulatory approval process.Related linkshttp://cannappscorp.com/https://thecse.com/en/listings/technology/global-cannabis-applications-corp🔴  Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe#AlwaysInvestedSTAY CONNECTED WITH THE CSE =============================📧 - NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe🎧 - PODCAST: https://blog.thecse.com/cse-podcasts/📸 - INSTAGRAM: https://www.instagram.com/canadianexchange/🤝 - LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange👥 - FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/🐦 - X: https://x.com/CSE_News📝 - BLOG: https://blog.thecse.com/🖥 - WEBSITE: https://thecse.com/📖 - MAGAZINE: https://issuu.com/thecse/docs©2026 CNSX Markets Inc. All rights reserved.